DR
Therapeutic Areas
Cytrellis Biosystems Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ellacor® System | Improvement in the appearance of moderate to severe wrinkles in the mid to lower face (Fitzpatrick skin types I-IV) | Commercial |
| ellacor® 2.0 | Next-generation update of the skin removal treatment system | Commercial Launch |
Leadership Team at Cytrellis Biosystems
DD
Dr. Denise Dajles
President & CEO
OB
Oliver Bennett
Chief Business Officer & General Counsel
BH
Bob Hinz
VP Operations
DK
Dr. Karyn Siemasko
VP Medical Affairs
SB
Sarah Brice, RN, BSN
VP Commercial Strategy
WG
William G. Austen, Jr. MD
Founder, Medical / Technology Advisor